Syndeo Biosciences

Syndeo Biosciences is a biotechnology company specializing in a proprietary site-specific bioconjugation platform designed to create next-generation therapeutic conjugates. The company's technology, the Syndeo™ platform, enables the precise attachment of various payloads to proteins, particularly targeting G protein-coupled receptors (GPCRs) to enhance drug efficacy and safety. Acquired by Sosei Heptares (now Nxera Pharma) in 2022, Syndeo's capabilities are integrated into the parent company's drug discovery engine to develop novel treatments for oncology, immunology, and other therapeutic areas. The platform is particularly noted for its ability to create stable, homogeneous drug conjugates with optimized pharmacological properties. Syndeo was originally incubated and launched by Versant Ventures to address limitations in existing conjugation methods.